Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
Christin Schütz(Philipps University of Marburg), Andreas Burchert(Philipps University of Marburg), Stephan Metzelder(Philipps University of Marburg), Rüdiger Hehlmann(Heidelberg University), Jolanta Dengler(Heidelberg University), Sabrina Inselmann(Philipps University of Marburg), Andreas Hochhaus(Jena University Hospital), Stefan Hanzel(Kempten University of Applied Sciences), Tim H. Brümmendorf(National University Cancer Institute, Singapore), Cornelia Brendel(Philipps University of Marburg), Andreas Neubauer(RWTH Aachen University), Ekkehard Eigendorff(Jena University Hospital), Thomas Illmer(Center for Systems Biology Dresden), Regina Herbst(Klinikum Chemnitz), Thoralf Lange, Cornelius F. Waller(University Medical Center Freiburg), Markus Pfirrmann(Ludwig-Maximilians-Universität München), Gernot Freunek, François‐Xavier Mahon(Institut Bergonié), Matthias Goebeler(University of Würzburg), Y. Wang(Philipps University of Marburg), Martin C. Müller(Universität Hamburg), Christian Dietz(Technische Universität Darmstadt), S Sausslele(Heidelberg University), Magdalena Huber(Philipps University of Marburg), Joëlle Guilhot(Inserm), Florian Finkernagel(Philipps University of Marburg)
Cited by 106
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
Diverse Applications of Nanomedicine
|ACS Nano|2017|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
|Leukemia|2016|849
A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group
|JNCI Journal of the National Cancer Institute|1998|820